Bioventus
Makes orthopedic treatments for knee pain, surgical bone repair, and fracture healing.
Something off on this page? Send us feedback.
Profile
Sells hyaluronic-acid knee injections, surgical biologics and ultrasonic tools, and EXOGEN bone stimulation through U.S. and international segments. Revenue is concentrated in the United States, and the business depends on physician adoption, reimbursement rules for viscosupplementation, and FDA/CMS treatment of bone-growth stimulators.
Centers on musculoskeletal products sold through Pain Treatments, Surgical Solutions, and Restorative Therapies. Pain Treatments includes DUROLANE, GELSYN-3, and SUPARTZ FX knee osteoarthritis injections, while Surgical Solutions covers bone-graft products and neXus ultrasonic surgical tools, and Restorative Therapies is now built around EXOGEN bone stimulation.
Sales run through U.S. and International segments and are concentrated in the United States. The portfolio was narrowed after CartiHeal obligations, Wound Business divestiture, and the Advanced Rehabilitation sale, leaving core orthopedic pain, surgery, and bone-healing franchises.
Execution depends on clinical adoption by orthopedic and pain-care providers, reimbursement for viscosupplementation products, and regulatory treatment of bone-growth stimulators such as EXOGEN.
Company facts
Categories
Key statistics
Year to date +92.1% · Average volume (30d) 754.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Reiterate | Buy | $15 | $19 | |
| Aug 6, 2026 | Craig-Hallum | Reiterate | Buy | $15 | $18 | |
| Aug 6, 2026 | Barrington | Target | $13 | $18 | ||
| Jun 16, 2026 | Canaccord Genuity | Reiterate | Buy | $12 | $15 | |
| Feb 9, 2026 | Barrington | Target | $13 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.22 | $0.22 | +1.7% | $155.4M | $153.2M | −1.4% | +13.71% |
| May 6, 2026Q1 FY26 | $0.09 | $0.15 | +66.7% | $129.9M | $132.1M | +1.7% | −2.47% |
| Mar 5, 2026Q4 FY25 | $0.22 | $0.24 | +9.1% | $154.9M | $157.9M | +1.9% | −7.58% |
| Nov 4, 2025Q3 FY25 | $0.22 | $0.15 | −30.2% | $155.7M | $138.7M | −11.0% | −2.25% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $123.9M | $147.7M | $138.7M | $157.9M | $132.1M | $153.2M | |
| Gross profit | $81.5M | $100.7M | $92.8M | $107.5M | $89.7M | $105.7M | |
| Operating income | $5.0M | $18.6M | $12.1M | $21.7M | $8.9M | $19.1M | |
| Net income | −$2.6M | $7.5M | $3.2M | $14.8M | $3.1M | $33.4M | |
| Diluted EPS | −$0.04 | $0.11 | $0.05 | $0.21 | $0.04 | $0.47 | |
| Gross margin | 65.8% | 68.2% | 67.0% | 68.1% | 67.9% | 69.0% | |
| Operating margin | 4.0% | 12.6% | 8.7% | 13.8% | 6.7% | 12.5% |
Fiscal years (4-quarter sums)FY21 $430.9M · FY22 $512.1M · FY23 $512.3M · FY24 $573.3M · FY25 $568.1M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 27, 2026Cash & short-term investments $29.5M · Total debt $263.7M · Total assets $673.3M · Shareholders' equity $228.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 67.75M · Float 46.69M · 68.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Essex Woodlands Management, Inc. | 13.02M | 19.22% | 13F | Aug 4, 2026 |
| Juniper Investment Company, LLC | 6.94M | 10.24% | 13F | Aug 14, 2026 |
| Nantahala Capital Management, LLC | 6.00M | 8.86% | 13F | Aug 19, 2026 |
| BlackRock, Inc. | 3.40M | 5.02% | 13G | Jul 27, 2026 |
| Royce & Associates LP | 1.83M | 2.71% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 11, 2026 | Michelle McMurry-Heath | director | −12,000 | $8.79 |
| Dec 4, 2025 | Guy P. Nohra | director | −10,000 | $7.57 |
| Nov 7, 2025 | Michelle McMurry-Heath | director | −17,701 | $7.42 |
Peers
- Anika Therapeutics
HA knee OA injections and regenerative orthopedics peer
- Sanofi (ADR)
Synvisc franchise rival in knee OA viscosupplementation
- Orthofix Medical
Bone stimulation and orthobiologics rival
- Zimmer Biomet
HA, PRP, and bone-graft overlap in orthopedics
- Medtronic
Scale spine-biologics rival in bone graft substitutes
- Integra LifeSciences
CUSA ultrasonic aspirator rival for neXus
- Stryker
Ultrasonic aspirator and bone-grafting rival
- Boston Scientific
Peripheral nerve stimulation rival through Nalu
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bioventus | $13.84 | −0.07% | $937.6M | 18.0 | 17.1 | 1.6 | +3.8% |
| Anika Therapeutics | $21.10 | −0.50% | $282.4M | — | 34.5 | 2.3 | +15.6% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Orthofix Medical | $9.70 | 0.00% | $392.1M | — | — | 0.5 | +3.9% |
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Integra LifeSciences | $16.89 | 0.00% | $1.31B | — | 6.6 | 0.8 | +0.8% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Median | 24.6 | 14.7 | 2.3 | +8.5% |